Morgan Stanley Clene Inc. Call Options Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CLNN
# of Institutions
54Shares Held
7.44MCall Options Held
48.1KPut Options Held
160K-
Vanguard Group Inc Valley Forge, PA2.62MShares$943,0930.0% of portfolio
-
Geode Capital Management, LLC Boston, MA947KShares$340,7510.0% of portfolio
-
Lunt Capital Management, Inc. Holladay, UT513KShares$184,6300.11% of portfolio
-
Scoggin Management LP New York, NY500KShares$180,0000.08% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL474KShares$170,6860.0% of portfolio
About Clene Inc.
- Ticker CLNN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,502,000
- Market Cap $22.9M
- Description
- Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...